Association of diabetes with atrial fibrillation types: a systematic review and meta-analysis by Alijla, Fadi et al.
Alijla et al. Cardiovascular Diabetology          (2021) 20:230  
https://doi.org/10.1186/s12933-021-01423-2
REVIEW
Association of diabetes with atrial fibrillation 
types: a systematic review and meta-analysis
Fadi Alijla1†, Chepkoech Buttia1†, Tobias Reichlin2, Salman Razvi3,4, Beatrice Minder5, Matthias Wilhelm2, 
Taulant Muka1, Oscar H. Franco1 and Arjola Bano1,2*  
Abstract 
Background: Atrial fibrillation (AF) is a common arrhythmia classified as paroxysmal and non-paroxysmal. Non-par-
oxysmal AF is associated with an increased risk of complications. Diabetes contributes to AF initiation, yet its role in AF 
maintenance is unclear. We conducted a systematic review and meta-analysis to summarize the evidence regarding 
the association of diabetes with AF types.
Methods: We searched 5 databases for observational studies investigating the association of diabetes with the 
likelihood of an AF type (vs another type) in humans. Study quality was evaluated using the Newcastle–Ottawa Scale. 
Studies classifying AF types as paroxysmal (reference) and non-paroxysmal were pooled in a meta-analysis using 
random effects models.
Results: Of 1997 articles we identified, 20 were included in our systematic review. The population sample size ranged 
from 64 to 9816 participants with mean age ranging from 40 to 75 years and percentage of women from 24.8 to 
100%. The quality of studies varied from poor (60%) to fair (5%) to good (35%). In the systematic review, 8 studies 
among patients with AF investigated the cross-sectional association of diabetes with non-paroxysmal AF (vs par-
oxysmal) of which 6 showed a positive association and 2 showed no association. Fourteen studies investigated the 
longitudinal association of diabetes with “more sustained” AF types (vs “less sustained”) of which 2 showed a positive 
association and 12 showed no association. In the meta-analysis of cross-sectional studies, patients with AF and diabe-
tes were 1.31-times more likely to have non-paroxysmal AF than those without diabetes [8 studies; pooled OR (95% 
CI), 1.31 (1.13–1.51),  I2 = 82.6%]. The meta-analysis of longitudinal studies showed that for patients with paroxysmal AF, 
diabetes is associated with 1.32-times increased likelihood of progression to non-paroxysmal AF [five studies; pooled 
OR (95% CI), 1.32 (1.07–1.62);  I2 = 0%].
Conclusions: Our findings suggest that diabetes is associated with an increased likelihood of non-paroxysmal 
AF rather than paroxysmal AF. However, further high quality studies are needed to replicate these findings, adjust 
for potential confounders, elucidate mechanisms linking diabetes to non-paroxysmal AF, and assess the impact of 
antidiabetic medications on AF types. These strategies could eventually help decrease the risk of non-paroxysmal AF 
among patients with diabetes.
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Introduction
Atrial fibrillation (AF) is the most common arrhyth-
mia, and it is associated with high risk of morbidity and 
mortality [1–4]. The incidence and prevalence of AF are 
increasing worldwide [5]. According to recent guidelines, 
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paroxysmal, persistent, long-standing persistent, and 
permanent AF (Additional file  1: Table  S1) [6]. While 
paroxysmal AF terminates within 7  days of onset, non-
paroxysmal AF (including persistent, long-standing per-
sistent, and permanent AF) lasts longer [6]. Patients who 
develop non-paroxysmal AF have a higher risk of adverse 
events (including all-cause mortality, thromboembolism, 
and hospitalization) compared to those with paroxysmal 
AF [7, 8]. Therefore, the identification of modifiable risk 
factors for non-paroxysmal AF is important to improve 
pathophysiological understandings about AF develop-
ment and to improve clinical management and prognosis 
for patients with AF by avoiding AF progression to non-
paroxysmal AF.
Diabetes mellitus represents a major risk factor for AF 
[9]. Patients with diabetes have a 34% greater risk of AF 
compared to those without diabetes [10]. Several mecha-
nisms, such as electrical, structural, and autonomic atrial 
remodelling, can explain the role of diabetes in the ini-
tiation of AF [11]. However, the impact of diabetes on 
the maintenance of sustained AF in non-paroxysmal AF 
remains unelucidated. To date, epidemiological studies 
have investigated the association of diabetes with differ-
ent classifications of AF types [12–15]. Various forms of 
“more sustained AF” (i.e., non-paroxysmal AF, perma-
nent AF, AF progression of paroxysmal to non-parox-
ysmal AF, and persistent to permanent AF) have been 
compared with forms of “less sustained AF.” However, 
results across studies have been inconsistent. For exam-
ple, one study reported that among patients diagnosed 
with AF, those with and without diabetes have significant 
differences in AF types [13], while another study found 
no differences [16]. A study including patients with par-
oxysmal AF reported an association between diabetes 
and the development of permanent AF [14], yet another 
study found no association [12]. These inconsistencies 
may also arise from differences in definitions of AF types, 
differences in characteristics of participants, or small 
study sample sizes. Overall, it is unclear whether patients 
with and without diabetes have differences in AF types.
We therefore performed a systematic review, which 
aimed to summarize evidence regarding the associa-
tion of diabetes with the likelihood of having a certain 
AF type, rather than another AF type. In order to pro-
vide insights concerning the role of diabetes on AF’s 
pathophysiology, we also performed a meta-analysis of 
diabetes’ association with the likelihood of having non-
paroxysmal AF rather than paroxysmal AF.
Methods
Data sources and search strategy
We conducted our systematic review following a recently 
published guide about performing systematic reviews 
and meta-analyses [17]. The guide was based on the Pre-
ferred Reporting Items for Systematic Review and Meta-
analyses recommendations [18]. We searched Embase, 
Medline Ovid, Cochrane Central, Web of Science Core 
Collection, and Google Scholar from inception until 
1 October 2021 [18]. To identify relevant articles, we 
combined (a) diabetes-related terms with (b) AF-related 
terms, such as “atrial,” “fibrillation,” “paroxysmal,” “per-
sistent,” “permanent,” and (c) article type. We excluded 
conference abstracts, letters to the editor, and editori-
als. (Additional file  1: Appendix A). We performed our 
search with the assistance of an experienced information 
specialist. We used EndNote to manage references.
Study selection
Eligibility criteria for included studies required (1) obser-
vational studies, including cross-sectional, prospective, 
case–control, nested case–control, or nested case-cohort 
studies of humans that (2) investigated the association of 
diabetes with the likelihood of having a certain AF type 
rather than another AF type and (3) provided informa-
tion about effect estimates (e.g., risk ratios, hazard ratios 
[HRs], and odds ratios [ORs]) with 95% confidence inter-
vals [95% CIs] or p-values). We excluded animal studies, 
reviews, meta-analyses, conference abstracts, conference 
proceedings, poster presentations, case-series, and let-
ters to the editor. We did not restrict publication year or 
language.
Two reviewers independently screened eligible cita-
tions by title and abstract. Furthermore, these two 
reviewers independently evaluated full texts of eligible 
articles. In cases of disagreement between reviewers, 
decisions were either made by consensus or in consul-
tation with a third reviewer. We hand searched the ref-
erence lists of included articles to identify additional 
studies.
Data extraction
Two authors independently extracted the following data 
from each study: first author`s last name, year of publi-
cation, country where the study was conducted, study 
population, number of participants at baseline, mean age, 
percentage of women, diabetes assessment, adjustments 
for potential confounders, outcome, follow-up time, and 
risk estimates with 95% CIs.
Quality assessment
Two authors independently performed quality assess-
ment of the included studies using the Newcastle–
Ottawa Scale (NOS) [19]. NOS rates study quality from 
0 to 9 stars according to three domains: selection, com-
parability, and outcome assessment. Based on thresholds 
for converting NOS scores into Agency for Healthcare 
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Research and Quality standards, we categorized study 
quality as (I) good (selection: 3–4 stars; comparability: 
1–2; outcome assessment: 2–3); (II) fair (selection: 2; 
comparability: 1–2; outcome assessment: 2–3); or (III) 
poor (selection: 0–1; comparability: 0; outcome assess-
ment: 0–1) (Additional file 1: Appendix B) [19, 20].
Statistical analyses
We included eligible studies that classified AF types into 
paroxysmal (reference) and non-paroxysmal AF in the 
meta-analysis. When applicable, ORs and 95% CIs were 
calculated using 2 by 2 tables. Effect estimates on the 
association of diabetes with the likelihood of non-parox-
ysmal AF (vs paroxysmal AF) were pooled using random 
effects models as described by DerSimonian and Laird; 
and forest plots were constructed [21]. We assessed het-
erogeneity using the  I2 statistic; we considered  I2 ≤ 25% 
low; 25% <  I2 < 75% moderate; and  I2 ≥ 75% high. In order 
to test the robustness of our results, we performed sev-
eral sensitivity analyses: (1) we recalculated estimates 
after removing studies one by one from the pooled analy-
sis to evaluate the role of individual studies on the over-
all results; (2) we performed subgroup analyses based 
on follow-up time (i.e., ≤ 1 year vs > 1 year) in our meta-
analysis of longitudinal studies; and (3) we also restricted 
our meta-analysis of longitudinal studies to studies that 
defined AF types in accordance with the guidelines [6]. 
We used funnel plots and Egger regression symmetry 
tests to evaluate the possibility of publication bias [22]. 
Statistical analyses were performed using Stata IC ver-
sion 15.1 (StataCorp LLC, Texas, USA).
Results
Literature search
After excluding duplicates, we identified 1,997 rele-
vant citations. We further screened studies by title and 
abstract, identifying 33 potentially relevant articles. After 
examining the article full texts, we identified 17 unique 
eligible articles. Our reference search yielded 3 additional 
articles, resulting in a total of 20 articles that we included 
in our systematic review. We present the results of our 
search strategy in Additional file 1: Fig. S1.
Characteristics of included studies
The population sample size ranged from 64 to 9816 par-
ticipants. The mean age ranged from 40 to 75 years. The 
percentage of women ranged from 24.8 to 100%. We 
present the general characteristics of the 20 eligible arti-
cles in Tables 1 and 2 and Additional file 1: Table S2. Of 
the 20 included studies, 5 were conducted in the United 
States [12, 23–26], 8 in Europe [7, 13–16, 27–29], 3 in 
Japan [30–32], 1 in Canada [33], 1 in Australia [34], and 2 
across several continents [35, 36]. Four studies diagnosed 
diabetes based on medical files and/or use of antidiabetic 
treatment [12, 23, 24, 32] (Tables 1 and 2). Sixteen studies 
did not provide information about assessment of diabe-
tes [7, 13–16, 25–31, 33–37] (Tables  1 and 2). We pro-
vide detailed information about the studies’ recruitment 
settings and periods, inclusion and exclusion criteria, AF 
monitoring, and AF definitions across studies in Addi-
tional file 1: Tables S2, S3 and S4.
Cross‑sectional association of diabetes with AF types
Our systematic review included 8 studies performed 
among patients with AF investigating the cross-sectional 
association of diabetes with the likelihood of having non-
paroxysmal AF rather than paroxysmal AF [13, 15, 16, 23, 
27, 28, 34, 36] (Table 1). Of the eight studies, six studies 
reported unadjusted estimates [13, 15, 23, 27, 28, 36], and 
two studies reported adjusted and unadjusted estimates 
[16, 34] (Table 1). Of the eight studies, six studies showed 
an association of diabetes with an increased likelihood of 
non-paroxysmal AF (with ORs varying from 1.2 to 1.8) 
[13, 23, 27, 28, 34, 36]; and 2 studies [15, 16] showed no 
association. We included these 8 studies in the meta-
analysis since all eight studies classified AF types into 
paroxysmal (reference) vs non-paroxysmal. The meta-
analysis showed that diabetes is associated with a 1.31-
times increased likelihood of having non-paroxysmal 
AF rather than paroxysmal AF with high heterogene-
ity (pooled OR [95% CI], 1.31 [1.13–1.51],  I2 = 82.6%) 
(Fig.  1). All studies we included in our meta-analysis 
provided unadjusted estimates. Results remained con-
sistent when pooling the two studies reporting adjusted 
estimates (including adjustments for age, sex, smoking, 
physical activity, cardiovascular risk factors, and cardio-
vascular diseases) with the six studies reporting unad-
justed estimates (pooled OR [95% CI], 1.29 [1.11–1.50], 
 I2 = 82.5%).
Longitudinal association of diabetes with AF types
Our systematic review included 14 studies investigat-
ing the longitudinal association of diabetes with AF 
types [7, 12, 14, 15, 23–26, 29–33, 35] (Table 2). Of the 
14 studies, six studies reported unadjusted estimates 
[7, 26, 31–33, 35], six studies reported adjusted esti-
mates [12, 14, 24, 25, 29, 30], and 2 studies reported 
adjusted and unadjusted estimates [15, 23] (Table  2). 
One study was performed among patients without AF 
at baseline; it showed no association between diabetes 
and the likelihood of developing non-paroxysmal AF 
rather than paroxysmal AF [25]. Five studies were per-
formed among patients with paroxysmal or persistent 
AF at baseline; they showed no association between 
diabetes and the likelihood of developing permanent 
AF [24, 30] or “AF progression” (i.e., paroxysmal to 
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persistent or permanent; persistent to permanent) over 
the follow-up period [15, 23, 29] (Table  2, Additional 
file  1: Table  S3). Eight studies included patients with 
paroxysmal AF at baseline; these studies investigated 
the association of diabetes with the likelihood of devel-
oping either “permanent AF” [12, 14], “recurrent AF” 
[31], “chronic AF,” or “non-paroxysmal AF” [7, 26, 32, 
33, 35] (Table  2, Additional file  1: Table  S3). Of these 
8 studies, 2 studies showed an association between 
diabetes and incident non-paroxysmal AF and perma-
nent AF, respectively (Table  2) [14, 32]. The other 6 
studies reported no association between diabetes and 
AF types (Table  2). We included 5 of 14 longitudinal 
studies in our meta-analysis; these 5 studies classified 
AF types into paroxysmal (reference) vs non-paroxys-
mal AF (Fig. 2). The meta-analysis showed that among 
patients with paroxysmal AF, diabetes was associated 
with a 1.32-times increased likelihood of developing 
non-paroxysmal AF with no heterogeneity (pooled OR 
[95% CI]; 1.32 [1.07–1.62];  I2 = 0%) (Fig. 2). All studies 
we included in our meta-analysis provided unadjusted 
estimates (Table 2, Fig. 2).
Sensitivity analyses
Results from our meta-analyses of cross-sectional and 
longitudinal studies did not change substantially after 
removing studies one by one from the analyses (Figs. 1, 
2, Additional file  1: Table  S5). In the meta-analysis of 
cross-sectional studies, the heterogeneity decreased 
from high  (I2, 82.6%) to moderate  (I2, 44%) after remov-
ing the study from Nabauer et  al. [13] (Additional 
file  1: Table  S5). In the meta-analysis of longitudinal 
studies, results remained consistent after performing 
subgroup analyses based on follow-up time and also 
after restricting the analysis to studies that defined AF 
types in accordance with guidelines (Additional file  1: 
Table S6).
Quality assessment
Of the 20 included studies, 12 (60%) were poor quality, 
1 (5%) fair quality, and 7 (35%) good quality. Out of 9 
stars, 6 studies scored 8 stars; 6 scored 6; 4 scored 5; 
and 4 scored 4. We present study quality assessment 
scores in Additional file 1: Table S7.
NOTE: Weights are from random effects analysis
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Fig. 1 Cross- sectional association of diabetes with non-paroxysmal AF (vs paroxysmal AF). Studies were included in the meta-analysis if they 
assessed the crosss-sectional association of diabetes with the likelihood of having non-paroxysmal AF (vs paroxysmal AF) among patients with AF; 
and provided poolable estimates. AF atrial fibrillation, OR odds ratio, 95% CI 95% confidence interval, IV inverse variance method, I-squared test for 
heterogeneity
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Assessment of publication bias
We show funnel plots for the cross-sectional and longitu-
dinal association of diabetes with non-paroxysmal AF (vs 
paroxysmal AF) in Additional file 1: Fig. S2. The Egger`s 
regression test did not show significant funnel plot asym-
metry (p-values 0.8 and 0.2, respectively). Hence, even 
though it should be noted that a maximum of eight stud-




To the best of our knowledge, ours is the first systematic 
review which summarizes the literature regarding the 
association of diabetes with AF types in humans. Fur-
thermore, this is the first meta-analysis which evaluates 
the likelihood of having non-paroxysmal AF rather than 
paroxysmal AF among patients with and without dia-
betes. We included various studies with relatively large 
sample sizes of participants with a wide range of ages 
from different parts of the world. The quality of studies 
spanned poor (60%), fair (5%), and good (35%). The meta-
analysis of cross-sectional studies suggested that patients 
with AF and diabetes have a 1.31-times higher likelihood 
of non-paroxysmal AF when compared to those with-
out diabetes. Our meta-analysis of longitudinal studies 
suggested that among patients with paroxysmal AF, the 
presence of diabetes is associated with 1.32-times higher 
likelihood of progression to non-paroxysmal AF. Addi-
tional sensitivity analyses provided similar findings. No 
evidence of publication bias was observed in included 
studies. The meta-analysis of cross-sectional studies indi-
cated a high heterogeneity. However, the heterogeneity 
was reduced  (I2 = 44%) in the “leave one out analysis” 
when removing the study from Nabauer et  al. [13]. The 
study from Nabauer et  al. was conducted over the time 
period 2004–2006, and it was the earliest investigation 
reporting on the cross-sectional association of diabetes 
with AF types, compared to the other studies. Hence, the 
result of the “leave-one out analysis” might be explained 
by the differences in the recruitment periods across stud-
ies, which can reflect differences over time in the defini-
tions of AF types and management of patients with AF. 
No heterogeneity was observed in the meta-analysis of 
longitudinal studies.
Mechanisms linking diabetes to non‑paroxysmal AF
Several mechanisms linking diabetes to non-paroxys-
mal AF can be proposed, including progression of atrial 
remodelling, worsening atrial cardiomyopathy, and 
development of cardiometabolic diseases [6]. Diabetes 
can lead to left ventricular hypertrophy and dysfunction, 
NOTE: Weights are from random effects analysis























Fig. 2 Longitudinal association of diabetes with non-paroxysmal AF (vs paroxysmal AF). Studies were included in the meta-analysis if they assessed 
the longitudinal association of diabetes with the likelihood of developing non-paroxysmal AF (vs paroxysmal AF) among patients with paroxysmal 
AF; and provided poolable estimates. AF atrial fibrillation, OR odds ratio, 95% CI 95% confidence interval, IV inverse variance method, I-squared test 
for heterogeneity
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which in turn increase atrial afterload and promote left 
atrial dilation. These conditions further foster the main-
tenance and recurrence of AF [26, 38]. Furthermore, 
diabetes is accompanied by an inflammatory state and 
oxidative stress, which are characterized by elevated lev-
els of C-reactive protein, tumor necrosis factor-alpha, 
interleukin-6, and reactive oxygen species [9, 39]. Inflam-
mation and oxidative stress are key mediators of proar-
rhythmic atrial remodeling among patients with diabetes 
[9, 39]. Diabetes is also associated with atrial fibrosis, 
which can promote gene expression that enhances the 
proliferation of fibroblasts and increases extra-cellular 
matrix secreting function [40]. This underlies the pro-
gression of AF to sustained forms by creating a long-term 
positive feedback loop—the so-called “AF begets AF” 
hypothesis [40]. Lastly, diabetes increases the risk of car-
diometabolic diseases, such as coronary artery disease, 
hypertension, heart failure, and chronic kidney disease, 
which further increase susceptibility to non-paroxysmal 
AF [7, 29, 40–42].
Lessons learned and future perspectives
Our study highlights the need for improving the quality 
of research about diabetes and AF types, while also pro-
posing new research directions for the future. First, the 
studies we included in our systematic review used differ-
ent categorizations of AF types, such as “paroxysmal” vs 
“non-paroxysmal” AF or “non-permanent” (i.e., parox-
ysmal or persistent) vs “permanent” AF. Although clas-
sification as paroxysmal or non-paroxysmal reflects the 
pathophysiology of AF, classification as non-permanent 
or permanent mainly reflects the therapeutic attitude of 
the patient and physician. For instance, older patients 
and those who have comorbidities are more likely to be 
considered as having permanent AF. Future studies aim-
ing to provide mechanistic insights about diabetes and 
AF types should thus focus on the classification of AF 
types as paroxysmal and non-paroxysmal AF [6].
Second, longitudinal studies included in our system-
atic review focused on several transitions of AF types. 
One study followed-up patients without AF and classified 
them based on AF development (i.e., no AF, paroxysmal 
AF, non-paroxysmal AF) [25]. Some studies followed-up 
patients with paroxysmal AF and classified them based 
on recurrence [12, 14, 31]; and other studies followed-up 
patients with paroxysmal or persistent AF and classified 
them based on AF progression (i.e., paroxysmal to per-
sistent or permanent; persistent to permanent) [15, 23, 
29]. In general, AF was documented by medical records, 
clinical visits, ECG recordings and/or Holter monitor-
ing, which were performed at baseline and over a lim-
ited number of follow-up visits. Indeed, AF is a dynamic 
disease. Over time, patients without AF can progress to 
paroxysmal or non-paroxysmal AF; and patients with 
paroxysmal AF can also progress to non-paroxysmal AF 
[33, 43]. Since evaluation requires a patient’s repeated 
long-term rhythm monitoring, evaluating AF types 
and progression can thus be challenging. In particular, 
the limited number and small frequency of AF evalua-
tions may impede the detection of paroxysmal AF. This 
may further hamper the comparison between AF types. 
Future studies with long-term follow-up need to compre-
hensively account for the progressive nature of AF and 
evaluate the role of diabetes in these dynamic processes.
Third, all studies in our systematic review that inves-
tigated the longitudinal association of diabetes with AF 
progression only evaluated diabetes status at baseline. 
Future studies should account for the potential develop-
ment of incident diabetes over time and also apply Cox 
models with time-varying covariates.
Fourth, most studies included in our systematic review 
did not describe how they defined diabetes. Some stud-
ies also used outdated terminology for AF types (e.g., 
“chronic AF”) [32, 33]. Future investigations thus need to 
define diabetes diagnosis in accordance with recommen-
dations and use the most recent terminology for and defi-
nitions of AF types [6, 44].
Fifth, we observed different levels of adjustments 
across studies in the systematic review; some studies did 
not adjust for potential confounders, some adjusted for 
age and sex, and others adjusted for cardiovascular risk 
factors and/or cardiometabolic diseases. In general, effect 
estimates attenuated after adjusting for cardiovascular 
risk factors (e.g., body mass index, hypertension, systolic 
and diastolic blood pressure) and/or cardiometabolic 
diseases (e.g., coronary heart disease, revascularization, 
valvular heart disease, heart failure, stroke, renal failure, 
and thyroid dysfunction). This can be explained by the 
fact that some of these factors can be on the path link-
ing diabetes to AF types. Future studies are warranted 
to clarify whether these factors have a mediating or 
confounding role in the association of diabetes with AF 
types. The studies that were eligible to be included in the 
meta-analyses of cross-sectional and longitudinal studies 
were mostly or completely unadjusted for potential con-
founders. In particular, adjusting for age and sex is cru-
cial when investigating the association of diabetes with 
AF types, and future studies need to account for these 
factors. Additional adjustments for confounders, includ-
ing alcohol, smoking, physical activity, education, medi-
cations, need to be performed accordingly.
Sixth, most studies included in the systematic review 
and meta-analysis did not take into account AF duration, 
which represents an important aspect in the examination 
of AF pattern. Hypothetically, underlying cardiovascular 
risk factors, such as diabetes, can be associated with a 
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longer duration of atrial remodelling. In turn, AF dura-
tion can be associated with an increased likelihood of 
non-paroxysmal AF [45]. However, in one of the studies 
of our systematic review, the association between diabe-
tes and non-paroxysmal AF became stronger and statisti-
cally significant after adjustment for AF duration, among 
other factors [15]. Future studies are needed to provide 
well characterized data on AF duration.
Although the results of our cross-sectional and longi-
tudinal analyses were consistent, we can not exclude the 
possibility of residual or unmeasured confounding, due 
to the observational character of our study. Future stud-
ies (e.g., Mendelian Randomization) need to establish if 
the association of diabetes with non-paroxysmal AF is 
causal.
Finally, the increased risk of bias in our systematic 
review and meta-analysis was mainly explained by con-
cerns related to definitions of AF types and adjustments 
for potential confounders. Our study highlights the need 
for improving these aspects and the overall quality of evi-
dence in the future.
Areas of limited evidence and future perspectives
Diabetes and non-paroxysmal AF We were able to exam-
ine two specific research questions in our meta-analyses: 
(1) “Among patients with AF, is the presence of diabetes 
associated with an increased likelihood of having non-
paroxysmal AF rather than paroxysmal AF?” (2) and 
“Among patients with paroxysmal AF, is the presence of 
diabetes associated with an increased likelihood of pro-
gression to non-paroxysmal AF?” Another important 
research question would be: “Among patients without AF, 
is the presence of diabetes associated with an increased 
risk of developing non-paroxysmal AF rather than par-
oxysmal AF?” Since only one study investigated this 
research question, we could not perform a meta-analysis 
on this matter [25]. Future studies are needed to evalu-
ate the association of diabetes with paroxysmal AF (vs no 
AF) and of diabetes with non-paroxysmal AF (vs no AF), 
and assess whether there are significant differences.
Glycemic control and non-paroxysmal AF Given the 
scarcity of evidence in the field, we could not perform a 
systematic review on the association between glycemic 
control and AF types. So far, increasing concentrations 
of glycated hemoglobin (HbA1c) and long term glyce-
mic variability have been prospectively associated with 
an increased risk of incident AF [46–48]. In accordance, 
we hypothesize that patients with diabetes and inade-
quate glycemic control are more likely to have non-par-
oxysmal AF rather than paroxysmal AF. This hypothesis 
was also confirmed in a study reporting a positive lin-
ear association of HbA1c levels with non-paroxysmal 
AF [25]. Future studies may need to evaluate whether it 
is useful to integrate diabetes and measures of glycemic 
control in risk scores for predicting the risk of incident 
non-paroxysmal AF among those without AF or with 
paroxysmal AF, respectively.
SGLT2 inhibitors and non-paroxysmal AF Recent 
studies have shown that sodium dependent glucose 
cotransporter 2 inhibitors have beneficial effects reduc-
ing the risk of incident AF and improving AF prognosis 
[49–52]. It can thus be assumed that this therapeutic 
option could also reduce the risk of non-paroxysmal 
AF. However, further studies are warranted to confirm 
this assumption.
Conclusions and implications
Our meta-analysis findings suggest that diabetes is asso-
ciated with increased likelihood of non-paroxysmal AF 
rather than paroxysmal AF. Our systematic review pro-
vides a comprehensive summary of evidence about the 
association of diabetes with AF types. These insights 
allowed us to identify current limitations and propose 
new directions for the improvement of future research 
about diabetes and AF types. Specifically, future studies 
should be based on classifying AF types into paroxysmal 
vs non-paroxysmal AF, properly adjusting for confound-
ers, accounting for incident diabetes using Cox models 
with time-varying covariates, as well as using standard 
definitions for diabetes and AF types in accordance with 
existing recommendations. Further high quality studies 
are needed to replicate our findings, examine causality, 
elucidate the exact mechanisms linking diabetes to non-
paroxysmal AF, evaluate the potential value of diabetes in 
predicting non-paroxysmal AF, and assess the role of gly-
cemic control and antidiabetic medications on AF types.
Our systematic review and meta-analysis provides 
insights into the pathophysiology of AF. Our findings 
suggest that patients with diabetes might need more 
attentive care than those without diabetes, in order to 
halt progression of AF burden and prevent adverse car-
diovascular events. Our data can also imply that the sub-
strate to ablate might be more complex in patients with 
diabetes than in those without diabetes. Future strate-
gies can foster prevention of non-paroxysmal AF by close 
monitoring of patients at high risk, increasing patient 
awareness, and involving patients in treatment plans. 
In addition, future studies could explore markers that 
may be used in the clinical setting to identify patients 
with diabetes at increased risk of AF progression, thus 
improving personalized care.
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